ORIGINAL RESEARCH article

Front. Public Health

Sec. Public Health Policy

Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1550712

This article is part of the Research TopicEmpowering Community Stakeholders: Novel Approaches to Address Health InequitiesView all 4 articles

Characterizing stakeholders in cancer primary prevention in European countries: an exploration of challenges and opportunities using a penta-helix framework

Provisionally accepted
Luis  RoxoLuis Roxo1,2,3*Ana  SantosAna Santos4Charis  GirvalakiCharis Girvalaki5Marius  GeantăMarius Geantă64P-CAN  WP2 study team4P-CAN WP2 study team7Mafalda  Sousa-UvaMafalda Sousa-Uva1,2,3
  • 1Department of Epidemiology, National Institute of Health Doctor Ricardo Jorge, Lisbon, Portugal
  • 2Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa, Lisbon, Portugal
  • 3Public Health Research Centre, NOVA National School of Public Health, Universidade NOVA de Lisboa, Lisbon, Portugal
  • 4CINTESIS@RISE, Department of Education and Psychology, University of Aveiro, Aveiro, Portugal
  • 5European network for smoking and tobacco prevention, Brussels, Belgium
  • 6Center for Innovation in Medicine, Bucharest, Romania
  • 74P-CAN Project, Bucharest, Romania

The final, formatted version of the article will be published soon.

Objectives: Cancer incidence has been increasing in Europe, with stark disparities between Western and Eastern regions. Cancer primary prevention (CPP) is a cost-effective strategy tackling lifestyle and risk factor exposure, but its implementation goes beyond the actions of the governments. This study aims to characterize stakeholders' role in CPP, using a penta-helix approach, with the objective of shedding a new light in the Iron Curtain of Cancer Cases.We followed a mixed-methods approach, with quantitative and qualitative data from CPP stakeholders from the public sector, academia/research, private sector, media and civil society. Snowball sampling was used to distribute a survey where participants (n=110) were asked which sector was the main driver of change, the most proactive and the most influential. Purposive sampling was used for semistructured interviews (n=33), where stakeholders were asked about their CPP activities, motivations, barriers and opportunities, and the role of other sectors. Countries were coded as Western or Eastern.Descriptive analysis was used for quantitative data, while thematic analysis was used for qualitative data.The public sector is viewed as the main driver of change, and the most proactive and influential in both Western and Eastern Europe. However, Eastern European countries emphasize the role of other sectors in CPP more strongly. Thematic analysis identified key roles and themes for the public sector (Strategy: "Looking after citizen's health", "Making the system work", "Providing care"), academia/research (Knowledge: "Scientific credibility", "Diversity of approaches", "Getting out of the lab", "Life in academia/research"), private sector (Responsibility: "Profit-oriented", "Resources and operational activities", "Ethics and responsibility"), media (Dissemination: "Capacity to reach people", "Diversity and scope", "Information and dissemination") and civil society (Engagement: "Proximity to people", "Advocacy and voice", "Do what others don't do"). Although no meaningful differences were identified between Western and Eastern countries, the results highlight opportunities for Eastern countries to reduce regional disparities.Overall, results point to the complementary role of the sectors, emphasizing that involving different stakeholders and promoting adequate collaborations between them is crucial to unravel the full potential of CPP.

Keywords: Cancer, Europe, mixed-methods, Primary Prevention, Stakeholders

Received: 23 Dec 2024; Accepted: 26 May 2025.

Copyright: © 2025 Roxo, Santos, Girvalaki, Geantă, WP2 study team and Sousa-Uva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Luis Roxo, Department of Epidemiology, National Institute of Health Doctor Ricardo Jorge, Lisbon, Portugal

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.